GlaxoSmithKline CEO's reform-minded rep under fire in China probe

Was GlaxoSmithKline ($GSK) CEO Andrew Witty looking in the wrong direction when he pledged to clean up his company's act? As the Wall Street Journal reports, Witty has focused heavily on reforming the company's U.S. operations by resolving government investigations in process when he took over and putting new policies in place to prevent a repeat. But as the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have been rigorous enough. Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.